These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21549519)

  • 1. Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients.
    Soto DE; Passarelli MN; Daignault S; Sandler HM
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1227-32. PubMed ID: 21549519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.
    Taguchi S; Fukuhara H; Azuma T; Suzuki M; Fujimura T; Nakagawa T; Ishikawa A; Kume H; Igawa Y; Homma Y
    BMC Urol; 2014 Oct; 14():81. PubMed ID: 25323845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
    Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage radiation therapy following radical prostatectomy. A national Danish study.
    Ervandian M; Høyer M; Petersen SE; Sengeløv L; Hansen S; Holmberg M; Sveistrup J; Meidahl Petersen P; Borre M
    Acta Oncol; 2016 May; 55(5):598-603. PubMed ID: 26399602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Ramey SJ; Agrawal S; Abramowitz MC; Moghanaki D; Pisansky TM; Efstathiou JA; Michalski JM; Spratt DE; Hearn JWD; Koontz BF; Liauw SL; Pollack A; Anscher MS; Den RB; Stephans KL; Zietman AL; Lee WR; Stephenson AJ; Tendulkar RD
    Eur Urol; 2018 Jul; 74(1):99-106. PubMed ID: 29128208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
    Kim D; Kim DY; Kim JS; Hong SK; Byun SS; Lee SE
    PLoS One; 2021; 16(9):e0256778. PubMed ID: 34506516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
    Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
    Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
    Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z
    Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.
    King CR; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
    Song C; Kim YS; Hong JH; Kim CS; Ahn H
    BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.